Biliary Tract Cancer

Biliary tract cancer is a group of cancers that start in the tubes and organs that carry and store bile. Bile is a yellow-green fluid the liver makes to help digest fat. These cancers can begin in the bile ducts inside the liver, the bile ducts outside the liver, or the gallbladder. Most of these tumors are adenocarcinomas, which means they grow from the lining cells that make mucus. Doctors often group them under the term biliary tract cancers (BTCs) and treat them in similar ways, while also paying attention to where they started and how far they have spread. Modern guidelines use imaging, blood tests, and sometimes small tissue samples to confirm the diagnosis, plan treatment, and check spread. Annals of Oncology+1

Biliary tract cancer is a group of cancers that start in the tubes and sacs that carry bile, including the bile ducts inside and outside the liver (cholangiocarcinoma) and the gallbladder. These cancers often grow quietly for a long time, so many people are diagnosed when the disease is already advanced. Treatment plans usually combine surgery (if possible), medicines like chemotherapy or targeted therapy, radiation therapy, and procedures to keep bile flowing. Choices are guided by tumor location (intrahepatic, perihilar, distal bile duct, or gallbladder), stage, liver function, and the tumor’s genes (for example FGFR2, IDH1, HER2, NTRK, MSI-H). Testing the tumor’s DNA is now routine because specific drugs can help certain gene-defined groups. JNCCN+1

Early-stage BTC may be cured with complete surgical removal and, for many patients, a period of chemotherapy afterward. For cancers that cannot be fully removed or that have spread, the goals are to help people live longer and live better by controlling growth, easing jaundice and itching, managing pain, and preserving nutrition and strength. Adding the immunotherapy durvalumab to first-line gemcitabine and cisplatin is now a standard option for many patients with advanced disease. JNCCN+1

---

Other names

• Biliary tract cancers (BTCs) — umbrella term for these tumors. Annals of Oncology

• Cholangiocarcinoma (CCA) — cancer of the bile ducts. Subtypes include intrahepatic (iCCA), perihilar (pCCA, “Klatskin”), and distal extrahepatic (dCCA). Cancer.gov

• Gallbladder cancer (GBC) — cancer starting in the gallbladder. Cancer.gov

---

Types

1. By location

   • Intrahepatic cholangiocarcinoma (iCCA): starts in small ducts inside the liver. It often looks like a mass in the liver on scans. Cancer.gov

   • Perihilar cholangiocarcinoma (pCCA/Klatskin): starts where the right and left hepatic ducts meet near the liver hilum, commonly causing jaundice by blocking bile flow. Cancer.gov

   • Distal extrahepatic cholangiocarcinoma (dCCA): starts in the duct closer to the small intestine. It often narrows the duct and blocks bile. Cancer.gov

   • Gallbladder cancer (GBC): starts in the gallbladder, the small pouch under the liver that stores bile. Cancer.gov

2. By growth pattern (especially for CCA)

   • Mass-forming: a lump or mass, often in the liver.

   • Periductal-infiltrating: spreads along the duct and causes long strictures.

   • Intraductal-growing: grows into the duct as papillary or polyp-like tissue. Annals of Oncology

3. By cell type (histology)

   • Adenocarcinoma (most common).

   • Less common: papillary, mucinous, squamous, and mixed types; in GBC, papillary type may carry a better outlook. Cancer.gov

---

Causes and Risk Factors

“Cause” means a strong driver. “Risk factor” means something that raises the chance. Having risk does not mean you will get cancer.

1. Primary sclerosing cholangitis (PSC): long-term inflammation and scarring of bile ducts; one of the strongest risks for cholangiocarcinoma. AASLD+1

2. Liver flukes (Opisthorchis viverrini, Clonorchis sinensis): parasites found in some Asian regions; chronic infection causes duct damage and cancer risk. PMC

3. Hepatolithiasis (bile duct stones): repeated irritation and infections inside ducts promote cancer changes. PMC

4. Bile duct cysts/choledochal cysts (including Caroli disease): abnormal dilated ducts that inflame easily; cancer risk rises with age. Annals of Oncology

5. Chronic biliary infections (recurrent cholangitis): repeated infections injure the duct lining and raise cancer risk over time. Annals of Oncology

6. Gallstones (large, long-standing): long-term irritation of the gallbladder lining raises gallbladder cancer risk. Cancer.gov

7. Porcelain gallbladder: heavy calcium deposits in the gallbladder wall related to chronic inflammation; classically linked with higher GBC risk. Cancer.gov

8. Chronic Salmonella Typhi carrier state: long-term infection of the gallbladder can increase GBC risk. Cancer.gov

9. Gallbladder polyps (≥1 cm or growing): larger polyps are more likely to harbor cancer. Cancer.gov

10. Cirrhosis of the liver: scarring from hepatitis B/C, alcohol, or fatty liver increases especially iCCA risk. Cancer Research UK

11. Hepatitis B or C virus infection: chronic liver inflammation and scarring add risk, especially for iCCA. Cancer Research UK

12. Metabolic dysfunction–associated steatotic liver disease (MASLD/NAFLD) and diabetes: metabolic inflammation in the liver modestly increases risk. ScienceDirect

13. Obesity: part of the metabolic risk cluster that raises biliary tract cancer risk over time. ScienceDirect

14. Smoking: toxins cause DNA damage and raise the risk for many digestive tract cancers, including biliary. Annals of Oncology

15. Older age: most cases occur in people over 60 because mutations and inflammation add up with time. Annals of Oncology

16. Sex and geography: risk patterns vary; for example, CCA is more common in some Asian regions due to flukes. Annals of Oncology

17. Industrial/toxin exposures (historic Thorotrast, some chemicals): rare today but linked to CCA in older literature; risk comes from DNA damage. Annals of Oncology

18. Biliary–enteric drainage or chronic duct injury (post-surgery strictures): long-term irritation promotes malignant change. Annals of Oncology

19. Family or genetic predisposition (rare): certain DNA repair defects or biliary syndromes can raise risk in a small subset. Annals of Oncology

20. Inflammatory bowel disease (through PSC link): people with PSC plus ulcerative colitis have particularly high CCA risk. AASLD+1

---

Common Symptoms

1. Jaundice (yellow skin/eyes): bile cannot drain, so bilirubin backs up in the blood and skin. Cancer.gov+1

2. Itching (pruritus): bile salts deposit in the skin and trigger severe itch. Cancer.gov

3. Dark urine and pale, clay-colored stools: bilirubin spills into urine but not into the gut. Cancer.gov

4. Right upper belly pain or discomfort: stretching of ducts or gallbladder and nearby inflammation cause pain. Cancer.gov

5. Fever/chills (especially with cholangitis): blocked ducts can get infected. Cancer.gov

6. Loss of appetite and early fullness: inflammation and tumor-related chemicals reduce hunger. Cancer.gov

7. Unplanned weight loss: the body burns energy fighting the tumor; intake often falls. Cancer.gov

8. Nausea/vomiting or indigestion: blockage and local irritation upset digestion. Cancer.gov

9. Fatigue and weakness: chronic illness, low intake, and poor bile flow reduce energy. Cancer.gov

10. Bloating: liver and gallbladder swelling or fluid in the belly (ascites) can cause fullness. Cancer.gov

11. Back or shoulder pain (referred): gallbladder or duct pain can be felt under the right shoulder blade. Cancer.gov

12. New-onset diabetes or worsening control (in some iCCA): liver disease can alter glucose handling. ScienceDirect

13. Courvoisier sign (palpably enlarged, nontender gallbladder with jaundice): suggests obstruction near the distal duct. Cancer.gov

14. Night sweats/low-grade fevers: systemic inflammation from cancer. Annals of Oncology

15. Generalized malaise: a “run-down” feeling common in many cancers. Cancer.gov

---

Diagnostic Tests

A) Physical Examination

1. General inspection for jaundice and scratch marks: shows bile buildup and chronic itch from blockage. Doctors also check for weight loss and dehydration. Cancer.gov

2. Abdominal palpation for tenderness or mass: right upper quadrant pain or a firm mass can suggest gallbladder or liver involvement. Cancer.gov

3. Liver size and surface assessment: an enlarged, firm edge suggests liver involvement or blockage causing congestion. Cancer.gov

4. Courvoisier sign: a smooth, enlarged, non-tender gallbladder with jaundice suggests a blockage below the cystic duct (often malignant). Cancer.gov

5. Lymph node check (e.g., left supraclavicular/Virchow node): enlarged nodes can point to spread. Annals of Oncology

B) Manual/Bedside Maneuvers

6. Murphy sign (inspiration arrest with RUQ palpation): more typical for acute cholecystitis but may appear with cancer-related inflammation. Helps the differential diagnosis. Cancer.gov

7. Percussion for liver span and ascites: detects enlargement or fluid that can accompany advanced disease. Cancer.gov

8. Scleral exam under natural light: subtle jaundice is easiest to see in the eyes first. Cancer.gov

9. Nutritional status (skin turgor, muscle wasting): malnutrition is common and influences treatment planning. Annals of Oncology

10. Pruritus severity check (sleep disturbance, excoriations): guides urgency of bile drainage for symptom relief. Cancer.gov

C) Laboratory & Pathology Tests

11. Liver tests (bilirubin, alkaline phosphatase, GGT, AST/ALT): cholestatic pattern (high bilirubin, ALP, GGT) suggests obstruction; AST/ALT may be mildly elevated. Cancer.gov

12. Tumor markers (CA 19-9 ± CEA): can support the diagnosis and help follow response; not specific enough alone. Cancer.gov

13. Rule-out IgG4-related sclerosing cholangitis (serum IgG4): important mimic that can look like cancer but needs steroids, not surgery. AASLD

14. Complete blood count and infection work-up: look for cholangitis (fever, high white cells) and anemia of chronic disease. Cancer.gov

15. ERCP brush cytology/biopsy: cells are collected from a stricture to look for cancer under the microscope; sensitivity improves with special DNA tests (e.g., FISH). Cancer.gov

16. EUS-guided fine-needle aspiration/biopsy (EUS-FNA/FNB): samples masses or nodes next to the bile duct with a small needle through the gut wall. Annals of Oncology

17. Surgical or percutaneous core biopsy (when appropriate): tissue confirmation for unresectable disease or before systemic therapy; may be skipped if a clearly resectable tumor is going straight to surgery. Cancer.gov

18. Molecular profiling of tumor tissue (e.g., IDH1/2 mutations, FGFR2 fusions): not needed to diagnose cancer but guides modern targeted therapy and trials. Annals of Oncology

D) Electrodiagnostic Tests (clarification)

There are no specific electrodiagnostic tests (like ECG/EMG) that diagnose biliary tract cancer. Doctors may use an ECG and other physiologic tests to check fitness for anesthesia and surgery, but these do not establish the cancer diagnosis. This category is noted for completeness. Annals of Oncology

E) Imaging & Endoscopic/Cholangiographic Tests

19. Right upper quadrant ultrasound: first-line, widely available; shows duct dilation, gallstones, masses, and guides further testing. Cancer.gov

20. Contrast-enhanced multiphasic CT scan (liver/pancreas protocol): maps the tumor, blood vessels, lymph nodes, and possible spread to plan surgery or stenting. Cancer.gov

21. MRI with MRCP: offers detailed pictures of the bile ducts without dye inside the ducts; excellent for defining strictures and planning treatment. Cancer.gov

22. Endoscopic ultrasound (EUS): high-resolution images from inside the stomach/duodenum; helps biopsy nearby nodes or distal duct masses. Annals of Oncology

23. ERCP (endoscopic retrograde cholangiopancreatography): injects contrast into the duct to see narrowings, allows brushings/biopsy, and can place stents to relieve jaundice and infection. Cancer.gov

24. Percutaneous transhepatic cholangiography (PTC): needle access through the liver to opacify ducts; useful when ERCP cannot reach, and for external/internal drainage. Cancer.gov

25. PET-CT (selected cases): may detect hidden spread and help staging when results will change management. Annals of Oncology

26. Staging laparoscopy: a small-incision camera checks for tiny metastases not seen on scans before major surgery. Cancer.gov

Non-pharmacological treatments (therapies & others)

1) Early palliative-care integration.
Palliative care supports symptom relief (pain, itching, nausea), emotional health, and decision-making from diagnosis onward. It improves quality of life and can reduce unplanned hospital use. Ask for a referral early; it works with oncology care, not instead of it. JNCCN

2) Nutrition counseling and medical nutrition therapy.
Weight loss and muscle loss are common in BTC. A dietitian can guide higher-protein meals, oral nutrition supplements, and—if needed—tube feeding or IV nutrition to maintain strength during treatment. Evidence-based nutrition guidelines recommend 25–30 kcal/kg/day and 1.0–1.5 g protein/kg/day, using enteral nutrition when oral intake is not enough. ESPN+2SCWD+2

3) Exercise and prehabilitation.
Simple, supervised aerobic and resistance exercise helps reduce fatigue, keep muscle mass, and improve function before and during therapy. Even short walking programs and light resistance bands can help if tailored to liver function and overall status. ESPN

4) Endoscopic biliary stenting (ERCP).
Plastic or metal stents placed endoscopically can drain blocked bile ducts, quickly lowering bilirubin, easing itching and infection risk, and enabling chemotherapy. Metal stents often last longer for malignant blockages. Choice depends on anatomy and goals. www.asge.org+1

5) EUS-guided or percutaneous biliary drainage (when ERCP fails).
If ERCP cannot access the blockage, endoscopic ultrasound–guided or percutaneous drainage can relieve jaundice. The approach is individualized by level of obstruction and expertise. giejournal.org+1

6) External-beam radiation therapy (EBRT).
Modern image-guided radiation can control local disease, treat pain, and help with bleeding or obstruction in selected patients with intrahepatic cholangiocarcinoma or extrahepatic disease who are not surgical candidates. Dosing and technique follow ASTRO guidance. practicalradonc.org+1

7) Stereotactic body radiotherapy (SBRT).
Focused high-dose radiation in a few sessions may control small liver lesions while sparing normal liver, especially when surgery is not possible. Suitability depends on tumor size, location, and liver reserve. practicalradonc.org

8) Photodynamic therapy (selected centers).
For some unresectable cholangiocarcinomas, photodynamic therapy via endoscopy can improve biliary drainage and symptoms when combined with stenting. It is considered in specialized settings. JNCCN

9) Pain management using the WHO ladder.
BTC pain can be treated stepwise with non-opioids, then weak and strong opioids as needed, plus bowel regimens and adjuvants (e.g., neuropathic agents). A palliative team helps balance relief and side effects. JNCCN

10) Itch (pruritus) management without drugs first.
Keep nails short, moisturize, use cool baths, and wear loose cotton clothing; stenting to improve bile flow is the most effective non-drug measure. Other steps (light therapy, behavioral strategies) may help. JNCCN

11) Psychological counseling.
Anxiety and low mood are common. Brief cognitive-behavioral therapy, mindfulness, and support groups can reduce distress and improve coping for patients and caregivers. JNCCN

12) Social work and financial counseling.
Navigating transportation, work, and treatment costs matters for adherence and well-being. Oncology social workers connect patients with aid programs and practical supports. JNCCN

13) Smoking cessation support.
Stopping smoking improves healing and may improve treatment tolerance and outcomes. Structured programs and counseling are recommended. JNCCN

14) Alcohol moderation/cessation aids.
Limiting alcohol helps protect the liver and reduces complications in those with underlying liver disease. Counseling and referral resources are advised. JNCCN

15) Vaccination review (HBV, influenza, pneumococcal).
Vaccinations reduce infection risk in immunocompromised patients and in those with chronic liver disease. HBV vaccination also prevents a key liver cancer risk factor. JNCCN

16) Management of cholangitis risk.
Education on fever and sepsis warning signs after stent placement plus rapid access to care is critical to prevent severe infections. www.asge.org

17) Lymphedema and postsurgical rehab (if resected).
Targeted physical therapy after major hepatobiliary surgery aids recovery, mobility, and return to daily tasks. JNCCN

18) Fertility and family planning counseling.
Discuss fertility preservation before chemotherapy in appropriate patients and family planning during immunotherapy. JNCCN

19) Advance care planning.
Documenting values and preferences (e.g., health care proxy) early ensures care matches patient goals through the course of illness. JNCCN

20) Clinical trial participation (where available).
Trials offer access to new targeted drugs, immunotherapies, or radiotherapy strategies; they are an important option in BTC. JNCCN

---

Drug treatments

1) Durvalumab (Imfinzi) + gemcitabine + cisplatin (first-line).
What it is: An immune checkpoint inhibitor (anti-PD-L1) added to standard gemcitabine/cisplatin. Why/Purpose: Improves survival in adults with locally advanced or metastatic BTC. How it works: Unblocks immune T-cells from PD-L1 suppression; chemo provides cytotoxic kill and may enhance tumor immunogenicity. Dose/Time: Per FDA label with gemcitabine/cisplatin on 21-day cycles; continue durvalumab if benefiting. Side effects: Immune inflammations (thyroid, liver, lungs, colon, skin), fatigue, cytopenias, nausea; urgent reporting is key. FDA Access Data+1

2) Gemcitabine (backbone chemo).
Class: Antimetabolite. Purpose: Core drug with cisplatin; also used with other agents. Mechanism: Incorporates into DNA, halting replication. Dose/Time: IV on days 1 and 8 of 21-day cycles (varies by regimen). Common effects: Low blood counts, fatigue, nausea, liver enzyme rises. (Use per label; disease-specific use guided by NCCN.) JNCCN

3) Cisplatin (backbone chemo).
Class: Platinum agent. Purpose: Paired with gemcitabine (± durvalumab) to improve outcomes. Mechanism: DNA cross-linker causing apoptosis. Dose/Time: IV day 1 of 21-day cycles (hydration required). Key risks: Kidney injury, neuropathy, hearing loss, nausea; careful monitoring and antiemetics required. JNCCN

4) Oxaliplatin (FOLFOX; second-line standard).
Class: Platinum. Purpose: With 5-FU/leucovorin (FOLFOX) after gemcitabine/cisplatin failure. Mechanism: DNA cross-linking. Dose/Time: Every 2 weeks with 5-FU/leucovorin. Effects: Neuropathy (cold-sensitive), cytopenias, nausea. (Use is NCCN-endorsed based on ABC-06; see guideline). JNCCN

5) 5-Fluorouracil (5-FU).
Class: Antimetabolite. Purpose: With oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) in later lines; radiosensitizer with EBRT. Mechanism: Thymidylate synthase inhibition → DNA disruption. Dose/Time: Bolus + infusional schedules vary. Effects: Mucositis, diarrhea, cytopenias, hand–foot syndrome. JNCCN

6) Capecitabine.
Class: Oral prodrug of 5-FU. Purpose: Adjuvant chemo after resection (BILCAP) and palliative combinations. Mechanism: Converted to 5-FU in tumor. Dose/Time: 14 days on, 7 off (typical). Effects: Hand–foot syndrome, diarrhea, fatigue. (Practice based on guidelines.) JNCCN

7) Pembrolizumab (Keytruda) for MSI-H/dMMR or TMB-H tumors.
Class: PD-1 inhibitor. Purpose: Tumor-agnostic use for unresectable or metastatic MSI-H/dMMR, or TMB-H ≥ 10 mut/Mb solid tumors (applies to BTC subsets). Mechanism: Restores anti-tumor T-cell activity. Dose/Time: Per label every 3 or 6 weeks. Risks: Immune-mediated toxicities (thyroid, hepatitis, colitis, pneumonitis). FDA Access Data+1

8) Ivosidenib (Tibsovo) for IDH1-mutant cholangiocarcinoma.
Class: IDH1 inhibitor. Purpose: For adults with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. Mechanism: Blocks mutant IDH1, reducing oncometabolite 2-HG and slowing growth. Dose/Time: Oral daily until progression/toxicity. Effects: Fatigue, diarrhea, QT prolongation (ECG monitoring advised). FDA Access Data

9) Pemigatinib (Pemazyre) for FGFR2 fusion/rearranged cholangiocarcinoma.
Class: FGFR inhibitor. Purpose: For previously treated, unresectable/metastatic intrahepatic cholangiocarcinoma with FGFR2 fusion/rearrangement. Mechanism: Blocks FGFR signaling driving growth. Dose/Time: Oral on 14-day on/7-day off cycles. Effects: Hyperphosphatemia, nail/skin changes, eye problems—baseline and periodic eye exams recommended. FDA Access Data+2PMC+2

10) Futibatinib (Lytgobi) for FGFR2-rearranged iCCA.
Class: Irreversible FGFR inhibitor. Purpose: For previously treated, unresectable/metastatic intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements. Mechanism: Covalent FGFR blockade. Dose/Time: 20 mg orally once daily. Effects: Hyperphosphatemia, nail/skin changes, eye toxicity; monitor phosphate and eyes. FDA Access Data+2FDA Access Data+2

11) Zanidatamab (Ziihera) for HER2-positive BTC.
Class: Bispecific anti-HER2 antibody. Purpose: Accelerated approval for previously treated unresectable/metastatic HER2-positive (IHC 3+) BTC based on response rate/duration; confirmatory trials ongoing. Mechanism: Dual HER2 epitope binding promotes receptor downregulation and ADCC. Dose/Time: Per label. Effects: Diarrhea, infusion reactions; monitoring required. FDA Access Data+2U.S. Food and Drug Administration+2

12) Larotrectinib (Vitrakvi) for NTRK fusion–positive solid tumors.
Class: TRK inhibitor. Purpose: Tumor-agnostic use when BTC carries an NTRK fusion and no good alternatives exist. Mechanism: Inhibits TRK A/B/C. Dose/Time: Oral; adult and pediatric dosing per label. Effects: Fatigue, dizziness, liver enzyme elevations. FDA Access Data+1

13) Entrectinib (Rozlytrek) for NTRK fusion–positive solid tumors.
Class: TRK/ROS1 inhibitor. Purpose: Tumor-agnostic, including rare NTRK-rearranged BTC. Mechanism: Inhibits TRK family and ROS1. Dose/Time: 600 mg once daily in adults. Effects: Edema, dizziness, liver enzyme rises, weight gain. U.S. Food and Drug Administration+1

14) Irinotecan (FOLFIRI).
Class: Topoisomerase-I inhibitor. Purpose: Later-line option with 5-FU/leucovorin for progressive BTC when platinum options are exhausted. Mechanism: Causes DNA strand breaks. Dose/Time: Every 2 weeks. Effects: Diarrhea (early/late), neutropenia—growth-factor support may be needed. (Guideline-supported use.) JNCCN

15) Carboplatin (for patients who cannot receive cisplatin).
Class: Platinum. Purpose: Substitute for cisplatin in selected patients (renal/hearing concerns). Mechanism: DNA cross-linking. Dose/Time: AUC-based dosing with gemcitabine or other partners. Effects: Myelosuppression (platelets), less nephrotoxicity than cisplatin. (Guideline-supported substitution.) JNCCN

16) Leucovorin (folinic acid) with 5-FU regimens.
Class: Reduced folate. Purpose: Enhances 5-FU binding to thymidylate synthase, improving 5-FU effect in FOLFOX/FOLFIRI. Dose/Time: Given with 5-FU in two-weekly cycles. Effects: Generally well tolerated; GI upset possible. (Guideline-supported.) JNCCN

17) Paclitaxel (select later-line regimens).
Class: Microtubule stabilizer. Purpose: May be used off-label in combinations or in trials for refractory disease; consider toxicity profile and prior therapy. Mechanism: Mitotic arrest. Effects: Neuropathy, alopecia, myelosuppression. (Use based on practice patterns/guidelines when appropriate.) JNCCN

18) Docetaxel (select later-line regimens).
Class: Microtubule inhibitor. Purpose: Considered in refractory disease in select cases; benefit is modest and toxicity can be limiting. Effects: Neutropenia, fatigue, edema. (Guideline context.) JNCCN

19) Nab-paclitaxel (investigational/center-specific regimens).
Class: Albumin-bound taxane. Purpose: Studied with gemcitabine/cisplatin; not standard everywhere—trial or center protocols guide use. Effects: Neuropathy, cytopenias. (Consider clinical trials.) PMC

20) Best supportive medications alongside anti-cancer therapy.
Examples: Antiemetics, growth-factor support when indicated, and bile-acid binders for itch. These do not treat the cancer but make anticancer therapy safer and more tolerable. ESPN

Important: Drugs #2–#6 and #14–#19 are used in BTC per contemporary guidelines; only some have BTC-specific wording on the FDA label. Molecularly targeted drugs (#8–#13) and durvalumab (#1) have FDA indications directly relevant to BTC or tumor-agnostic scenarios that include BTC. Always match the drug to a tested biomarker. JNCCN

---

Dietary molecular supplements

1) Vitamin D (if deficient).
Vitamin D deficiency is common in cancer and chronic cholestasis. Correcting deficiency supports bone and muscle health during therapy. Typical maintenance is 600–800 IU/day; higher repletion may be prescribed for deficiency after blood tests. Avoid mega-doses unless advised; too much can harm kidneys and heart. Office of Dietary Supplements

2) Omega-3 fatty acids (EPA/DHA).
Fish-oil omega-3s may help appetite, weight maintenance, and inflammation in cancer-related weight loss when added to nutrition support. Doses often range 1–2 g/day EPA+DHA, with monitoring for bleeding risks when on anticoagulants. Office of Dietary Supplements

3) Curcumin (turmeric extract).
Curcumin is under study for symptom relief and biologic effects in cancer, but evidence is not strong enough to claim treatment benefit. If used, standardized products with meals (e.g., 500–1000 mg/day) are common; watch for drug interactions and GI upset. Cancer.gov+1

4) Selenium (avoid excess).
Selenium supports antioxidant enzymes and immune function, but high doses can be toxic. Most adults meet needs from food; 55 µg/day is the RDA, and 400 µg/day is the tolerable upper limit. Supplement only if low or if advised. Office of Dietary Supplements

5) Zinc (when deficient).
Zinc deficiency worsens taste changes and wound healing. Supplement only after checking levels; typical short courses are 20–40 mg elemental zinc/day with food. Long-term high doses can cause copper deficiency. Office of Dietary Supplements

6) Probiotics (selected strains).
Some patients use probiotics during antibiotics or chemo-related diarrhea. Evidence varies by strain; immunocompromised patients must discuss risks with their team first. NCCIH

7) Protein supplements (whey/plant blends).
Shakes or powders help reach protein targets when appetite is low. Aim for 1.0–1.5 g/kg/day total protein from food plus supplements as guided by a dietitian. ESPN

8) Branched-chain amino acids (BCAAs).
BCAAs may aid muscle maintenance in some liver-related conditions; use only with dietitian/physician guidance due to variable evidence. ESPN

9) Soluble fiber (psyllium, oats).
May help with diarrhea after stenting or chemotherapy and supports gut health; increase gradually with fluids to avoid bloating. ESPN

10) Multivitamin at RDA levels.
A standard once-daily multivitamin can cover basic micronutrient needs when intake is poor. Avoid high-dose antioxidant cocktails during radiation or chemo unless advised. ESPN

---

Immunity-booster / regenerative / stem-cell” drugs

There are no FDA-approved “stem-cell drugs” or regenerative medicines that treat biliary tract cancer. Instead, clinicians use evidence-based immunotherapy and blood-forming growth factors to support patients and enable treatment. Unregulated stem-cell products should be avoided. JNCCN

1) Durvalumab (immune checkpoint inhibitor).
Helps the immune system recognize and attack cancer when paired with gemcitabine/cisplatin in advanced BTC. This is the main immune therapy with a BTC-specific FDA indication. FDA Access Data

2) Pembrolizumab (immune checkpoint inhibitor).
Used when the tumor is MSI-H/dMMR or TMB-H; this is tumor-agnostic and can apply to BTC subsets. FDA Access Data

3) Filgrastim (G-CSF).
A growth factor that stimulates white blood cell recovery during chemotherapy to lower infection risk; not an anti-cancer drug but helps keep chemo on schedule. (Use per label and guidelines.) ESPN

4) Pegfilgrastim (long-acting G-CSF).
Single post-chemo dose can prevent severe neutropenia in higher-risk regimens; timing and indications follow supportive-care guidelines. ESPN

5) Epoetin alfa or darbepoetin alfa (ESAs).
Considered for chemo-induced anemia in selected patients after risk–benefit discussion; they reduce transfusions but have safety cautions (thromboembolism). ESPN

6) Sargramostim (GM-CSF).
Less commonly used; may aid white cell recovery in certain settings. Decisions are individualized. ESPN

---

Surgeries

1) Bile duct resection with reconstruction (hepaticojejunostomy).
For selected extrahepatic cholangiocarcinomas, surgeons remove the involved duct and nearby tissue and rebuild bile flow by joining bile ducts to the small bowel, aiming for complete cancer clearance (R0 margins). JNCCN

2) Liver resection (segmentectomy/lobectomy or extended hepatectomy).
For intrahepatic cholangiocarcinoma or perihilar tumors, removing the liver part that contains the tumor plus lymph nodes offers the best chance of cure when margins can be cleared and the liver remnant will function safely. JNCCN

3) Pancreaticoduodenectomy (Whipple) for distal bile duct cancer.
Removes the head of pancreas, distal bile duct, gallbladder, and part of small intestine to clear distal cholangiocarcinoma with curative intent when feasible. JNCCN

4) Lymphadenectomy.
Regional lymph node removal provides staging and may improve local control when done with curative resections. JNCCN

5) Liver transplantation in very select cases.
Under strict protocols (e.g., certain early unresectable perihilar tumors with neoadjuvant therapy), transplant can be considered in expert centers. Selection is stringent. JNCCN

---

Preventions

1. Hepatitis B vaccination and treatment of chronic viral hepatitis to lower liver cancer risk overall. JNCCN

2. Avoid eating raw/undercooked freshwater fish in regions where liver flukes are common; treat parasitic infections promptly. JNCCN

3. Manage primary sclerosing cholangitis (PSC) with regular specialist follow-up and surveillance. JNCCN

4. Do not smoke; seek help to quit. JNCCN

5. Limit alcohol to protect the liver. JNCCN

6. Maintain healthy weight and treat diabetes/NAFLD. JNCCN

7. Address congenital biliary cysts/abnormalities per surgical advice. JNCCN

8. Follow workplace safety if exposed to industrial chemicals; use protective equipment. JNCCN

9. Regular medical care if you have gallstones, PSC, viral hepatitis, or cirrhosis. JNCCN

10. Participate in surveillance if you are high-risk (e.g., PSC), as advised by specialists. JNCCN

---

When to see a doctor

See a doctor now if you notice yellowing of skin/eyes, very dark urine, pale stools, severe itching, fever with chills, right-upper-abdominal pain, or unexplained weight loss. These can be signs of bile-duct blockage or infection (cholangitis) and need urgent care—especially after a stent. People with PSC, chronic hepatitis, or previous biliary surgery should report new symptoms early and follow surveillance plans. www.asge.org+1

---

What to eat” and “what to avoid

Eat more: small, frequent, high-protein meals (eggs, fish, lean meat, dairy, legumes), healthy fats (olive oil, avocado), soft fruits/vegetables, whole-grain carbs, and oral nutrition shakes if needed—adjusted for nausea or diarrhea. Avoid or limit: heavy alcohol, extremely fatty fried foods if they worsen symptoms, unpasteurized foods when neutropenic, and raw freshwater fish in fluke-endemic areas. Tailor fiber and lactose to tolerance; a dietitian can personalize plans through treatment. ESPN+1

---

Frequently Asked Questions

1) Is biliary tract cancer curable?
Sometimes—if found early and removed completely by surgery. Many cases are advanced at diagnosis; then the goal is to live longer and better with combined treatments. JNCCN

2) Why is genetic testing of the tumor important?
Certain gene changes (FGFR2, IDH1, HER2, NTRK; MSI-H/TMB-H) point to effective targeted or immune therapies. Ask your team to run a broad panel on the tumor (or blood). JNCCN

3) What is the current first-line standard for advanced BTC?
Gemcitabine + cisplatin plus durvalumab for many patients, if appropriate. FDA Access Data

4) If the cancer grows after first-line therapy, what next?
FOLFOX is a guideline-supported option; targeted or immune therapies depend on biomarkers (FGFR2, IDH1, HER2, NTRK, MSI-H/TMB-H). JNCCN

5) Can stents replace chemotherapy?
No. Stents relieve blockage and symptoms so you can receive systemic therapy safely. www.asge.org

6) Is radiation therapy used?
Yes, for local control or symptom relief in selected cases; techniques and doses follow ASTRO guidance. practicalradonc.org

7) Are there FDA-approved drugs specifically for BTC?
Yes: durvalumab (with gem/cis) and zanidatamab (HER2-positive BTC). Others are tumor-agnostic or biomarker-specific (ivosidenib, pemigatinib, futibatinib, larotrectinib, entrectinib). FDA Access Data+5FDA Access Data+5FDA Access Data+5

8) Should I take supplements?
Only to fill gaps (e.g., vitamin D if low, omega-3 for appetite/weight) and always tell your oncology team to avoid interactions. Office of Dietary Supplements+1

9) Does immunotherapy help everyone?
No. It helps specific groups (e.g., with durvalumab plus chemo, or MSI-H/TMB-H tumors). Biomarker testing guides use. FDA Access Data+1

10) Are “stem-cell therapies” for BTC available?
No approved stem-cell drugs treat BTC. Be cautious of unregulated clinics. JNCCN

11) Will I lose weight during treatment?
Many patients do; early dietitian input helps maintain calories and protein and may reduce complications. ESPN

12) How often do stents need changing?
Plastic stents often require earlier exchange; metal stents last longer but are not always removable. Your team tracks bilirubin and symptoms to plan exchanges. www.asge.org

13) Can surgery be done after chemotherapy?
Sometimes chemotherapy shrinks or stabilizes disease enough to allow surgery; decisions are made by a multidisciplinary team. JNCCN

14) Should I join a clinical trial?
If eligible, yes—trials are key in BTC and may offer new options. JNCCN

15) What follow-up is typical?
Regular visits with exams, liver tests, tumor markers, and imaging to watch for recurrence or stent issues; schedules vary by treatment and stage. JNCCN

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 25, 2025.

PDF Documents For This Disease Condition References